**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 58867

**Manuscript Type:** MINIREVIEWS

**Modern surgical strategies for perianal Crohn's disease**

Zabot GP *et al*. Surgical strategies for perianal CD

Gilmara Pandolfo Zabot, Ornella Cassol, Rogerio Saad-Hossne, Willem Bemelman

**Gilmara Pandolfo Zabot,** Department of Coloproctology, Hospital Moinhos de Vento, Porto Alegre 90035-902, RS, Brazil

**Ornella Cassol,** Department of Surgery, Hospital de Clínicas de Passo Fundo, Passo Fundo 99010-260, RS, Brazil

**Rogerio Saad-Hossne,** Department of Internal Medicine, São Paulo State University (Unesp), Medical School, Botucatu 18618687, São Paulo, Brazil

**Willem Bemelman,** Department of Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 19268, Netherlands

**Author contributions:** Zabot GP and Cassol OS designed and performed the research, analyzed the data and wrote the paper; Bemelman W analyzed the data and wrote the paper; Saad Hossne R designed the research; all authors read and approved the final manuscript.

**Corresponding author: Gilmara Pandolfo Zabot, MSc, Surgeon,** Department of Coloproctology, Hospital Moinhos de Vento, R. Ramiro Barcelos, 910 - Moinhos de Vento, Porto Alegre 90035-902, RS, Brazil. gilmarapandolfo@terra.com.br

**Received:** August 13, 2020

**Revised:** September 5, 2020

**Accepted:** September 29, 2020

**Published online:** November 14, 2020

**Abstract**

One of the most challenging phenotypes of Crohn’s disease is perianal fistulizing disease (PFCD). It occurs in up to 50% of the patients who also have symptoms in other parts of the gastrointestinal tract, and in 5% of the cases it occurs as the first manifestation. It is associated with severe symptoms, such as pain, fecal incontinence, and a significant reduction in quality of life. The presence of perianal disease in conjunction with Crohn’s disease portends a significantly worse disease course. These patients require close monitoring to identify those at risk of worsening disease, suboptimal biological drug levels, and signs of developing neoplasm. The last 2 decades have seen significant advancements in the management of PFCD. More recently, newer biologics, cell-based therapies, and novel surgical techniques have been introduced in the hope of improved outcomes. However, in refractory cases, many patients face the decision of having a stoma made and/or a proctectomy performed. In this review, we describe modern surgical management and the most recent advances in the management of complex PFCD, which will likely impact clinical practice.

**Key Words:** Crohn’s disease; Inflammatory bowel disease; Surgical treatment; Perianal fistulas; Anorectal fistula

**Citation:** Zabot GP, Cassol O, Saad-Hossne R, Bemelman W. Modern surgical strategies for perianal Crohn's disease. *World J Gastroenterol* 2020; 26(42): 6572-6581

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i42/6572.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i42.6572

**Core Tip:** Perianal Crohn’s disease (CD) occurs in up to 50% of patients who also have symptoms in other parts of the gastrointestinal tract. One of the most challenging phenotypes of CD is perianal fistulizing disease. Treatment is difficult, often requiring more aggressive medical and surgical interventions than luminal disease. Seton placement is the most common technique. However, with the advent of biological therapy, especially anti-TNF agents (infliximab and adalimumab), the approach to these fistulas has changed. Thus, this article aims to review the methods currently available for the management of perianal fistulizing disease.

**INTRODUCTION**

In Crohn’s disease (CD), perianal symptoms occur in up to 50% of patients with concurrent symptoms involving other portions of the gastrointestinal tract; in 5% of cases, perianal symptoms occur as the first manifestation of CD[1]. A challenging phenotype of CD is perianal fistulizing CD (PFCD), an aggressive, debilitating condition associated with significant morbidity that can negatively affect quality of life[2]. Treatment is difficult, often requiring more aggressive medical and surgical interventions than luminal disease. In addition, it predicts a worse disease course, requiring rigorous monitoring to identify those who are at risk of worsening, sub-optimal levels of biological drugs, and signs of neoplasia[3].

**PATHOPHYSIOLOGY**

Although the pathophysiology of cryptoglandular fistulas is well understood, that of CD-related fistulas has not yet been defined. Some theories have been proposed, but none have been confirmed[4].

**CLASSIFICATION**

Historically, perianal fistulas have been classified according to Parks’ anatomical model[5]. However, the American Gastroenterology Association has proposed that PFCDs should be classified into 2 categories: Simple and complex (*i.e.*, those with a high internal orifice and multiple or rectovaginal fistulas associated with abscesses or stenosis)[6]. The Van Assche score assesses the severity of CD throughout the anal canal based on magnetic resonance imaging findings[7].

The treatment of PFCD has traditionally been surgical, and seton placement is the most common technique. However, with the advent of biological therapy, especially anti-TNF agents (infliximab and adalimumab), the approach to these fistulas has changed. Thus, this article aims to review the currently available methods for managing PFCD.

**TREATMENT OF PERIANAL FISTULAS IN CD**

The initial approach is to control sepsis and take measures to prevent recurrent abscesses and the appearance of additional tracts by seton placement. Cutting setons should be avoided due to the risk of fecal incontinence[8].

**SIMPLE FISTULAS**

Fistulotomy is appropriate for superficial or low transsphincteric fistulas without associated proctitis, in addition to subanodermal, submucosal and subcutaneous fistulas. The recurrence rate is low (< 10%)[8]. However, incontinence rates vary from 0% to 50%, which leads to conservative techniques, such as seton placement[4]. Fistulotomy should not be performed anteriorly due to the risk of keyhole defects at the site where the sphincter is shortest, particularly in women. In the presence of proctitis, the fistulotomy wounds might not heal.

**COMPLEX FISTULAS**

Complex fistulas require an average of 6 procedures, while simple fistulas require 3 procedures[4]. At 10 years of follow-up, one-third require diversion and 13% require a proctectomy[9].

**TREATMENT OPTIONS FOR COMPLEX FISTULAS**

***Long-term setons***

Non-cutting setons can be maintained long term, *i.e.*, months or years. Two issues remain controversial during combination therapy (anti-TNF): Timing of withdrawal and number of procedures. The absence of secretion and proctitis are important factors. According to GETECCU recommendations, it is the option of choice in the presence of proctitis[10]. Kotze *et al*[11] found that the average time until seton removal was 7.3 mo, ranging from 1 to 36 mo. The advantages of this technique are the low cost, the prevention of new abscesses or recurring tracts, and a decreased need for temporary or permanent stoma, in addition to the low rate of reintervention (10% to 20%)[8]. On the other hand, the fistula does not close with the seton *in situ*, and the rate of clinical closure of the fistula after removal is 42% when used alone and 64% when in combination therapy with anti-TNF[12]. Another issue to be addressed is patient quality of life. The seton should be removed if the treatment goal is to close the fistula, usually prior to the end of the induction phase of TNF-inhibitors[13,14] (Table 1)[15-18].

***Endorectal advancement flap***

For endorectal advancement flap procedures, a tissue flap is mobilized from the mucosa, submucosa, or circular muscle layer of the rectum and advanced to cover the fistula’s internal opening, resulting in an intact sphincter apparatus. Healing of the excluded fistula pathway is expected over time. In the absence of proctitis or stenosis, this is a good therapeutic option with the advantage of avoiding extensive or difficult-to-heal wounds and a success rate of approximately 50%[10,19] (Table 2)[20-25].

***The*** ***ligation of the intersphincteric fistula tract***

The procedure for ligation of the intersphincteric fistula tract (LIFT) involves the ligation and removal of the fistula pathway via the intersphincteric space, followed by removal of the remaining fistulous tract by curettage and closure of the defect by suture in the external sphincter[26], so that the sphincter is not affected[27]. Kamiński *et al*[28] followed 23 patients with transsphincteric fistulas due to CD who were treated with LIFT. After 23 mo the healing rate was 48%. However, most reports of LIFT procedures describe patients without CD, and only a few studies have been published exclusively on PFCD treatment.

In CD, patients without proctitis who have lateral fistulas with long tracks, previous seton treatment, and small intestine disease would be the best candidates for the LIFT procedure. However, prospective randomized studies comparing LIFT to other techniques are needed to define the role of this method in the treatment algorithm for PFCD[29] (Table 3)[24,25,27,28].

***Fibrin glue and plugs***

Two anal fistula plugs are frequently used in the management of perianal fistulas: The Surgisis (Cook Surgical, Bloomington, IN, United States), a bioabsorbable xenograft made of lyophilized porcine intestinal submucosa; and the GORE (Bio-A; WL Gore and Associates, Flagstaff, AZ, United States), a synthetic plug made of polyglycolic acid and trimethylene carbonate, which contains 2 absorbable synthetic materials in the fistula path that allow fixation to the fistula’s internal opening[13]. The basic principle of the plug's action is to occlude the fistula path and promote healing. A controlled, randomized, multicenter study by the GETAID group compared the removal of the seton alone (control group) with plug insertion and found a healing rate of 31.5% in the plug group and 23.1% in the group control[30].

Heterologous fibrin glue is a 2-component material whose first component consists of fibrinogen, factor XIII, plasminogen, and aprotinin, whereas the second component consists purely of human thrombin. Simultaneous injection of the 2 components creates a fibrin clot that will mechanically seal the fistula path. Grimaud *et al*[31] conducted the first randomized, controlled clinical trial using fibrin glue to treat PFCD. They found healing rates of 38% in the glue group and 16% in the control group[31]. With unfavorable results for PFCD healing, both techniques were abandoned[4] (Table 4)[32-36].

***Video-assisted anal fistula treatment***

The main steps in Video-assisted anal fistula treatment (VAAFT) include excision of the fistula’s external orifice, insertion of a fistuloscope to visualize the main and secondary pathways, correction of the location of the internal orifice under direct vision and irrigation, followed by electrocauterization of the paths. Schwander, the first author to demonstrate the results of VAAFT through a prospective, randomized study, compared the results of the VAAFT with the endorectal advancement flap technique. After a 9-mo follow-up, the success rate was 82% (9/11)[37]. Since this is a high-cost method with a long learning curve, the results of long-term studies are necessary[10,28] (Table 5)[37-40].

***Fistula-tract Laser Closure***

Lasers were first described in perianal fistula treatment in 2006. A carbon dioxide laser was used in 27 patients with CD, and most improved[41]. In 2011, Wilhelm described a new surgical technique using a radial laser probe [Fistula-tract Laser Closure (FiLaCTM), Biolitec AG, Jena, Germany] to treat PFCD[42]. The basic principle of this technique is to destroy the epithelium of the fistulous path with the laser, although without direct visualization. In the initial study with this technique the internal orifice was closed with advancement of the endorectal flap. Wilhelm recently performed a for 2-year follow-up of 13 patients who underwent FiLaC combined with endorectal advancement flap and observed a 69% primary healing rate, which rose to 92% after the second surgery (secondary healing)[43]. The main advantages of this procedure are a shorter learning curve compared to VAAFT, faster recovery, and preservation of the sphincter. The disadvantages are the cost of the equipment and the absence of direct visualization of the paths. Thus, secondary paths may not be visualized and the healing rate could be reduced[29].

A recently published systematic review and meta-analysis concluded that FiLaC can be considered an effective and safe sphincter preservation technique with low complication rates. However, the review emphasized that studies comparing the laser to other techniques will be necessary to substantiate these promising results[44] (Table 6)[41,43,45,46].

***Fistulectomy with primary sphincter reconstruction***

Recent retrospective studies have assessed fistulectomy with primary sphincter reconstruction, finding excellent results. After an average follow-up of 11 mo (7 to 200 mo), the primary healing rate was 88.2%, with low recurrence rates[47]. However, no prospective studies have been published yet[28] (Table 7)[47,48].

***Stem cell injection***

The use of mesenchymal stem cells (MSC) is the most recent and promising strategy in PFCD treatment. MSC are a cell population similar to fibroblasts that can differentiate into several mesodermal cell lines[5]. They have potent anti-inflammatory and immunomodulatory activity[49]. The use of MSC in PFCD treatment is supported by the hypothesis that epithelial defects give rise to fistulas, which are maintained open by continuous inflammation occurring along the path. Injection of MSC into the fistula pathway is believed to reduce inflammation, thus promoting its healing[3]. MSC may be derived from adipose system (adipose stem cells – ASC) or from bone marrow. Despite the lack of clinical trials comparing bone marrow MSC to ASC, there are some reports of potential advantages of using ASC. Liposuction or excisional fat biopsy can be used to ensure the harvest of a large number of stable raw cells that are readily available for clinical use. ASC also have a greater proliferative and angiogenic capacity, in addition to being more genetically and morphologically stable[5]. However, to date, no study has directly compared the use of autologous *vs* allogeneic MSC. It may take several weeks to expand autologous MSC *in vitro*. In addition, the patient's age and disease status can also affect cell quality. Nevertheless, allogeneic therapy with MSC has gained increasing popularity because of the immediate availability of high-quality cells for treatment. Thus, allogeneic products are likely to be used in the future[50].

Evidence about the effectiveness of ASC for complex PFCD treatment comes mainly from the ADMIRE-CD, a multicenter, randomized, double-blind, placebo-controlled study of 212 patients who did not respond to conventional medical treatment and were randomly assigned to receive an injection of 120 million ASC into the fistula pathways or placebo. Patients were allowed concomitant treatment with immunosuppressants and/or anti-TNFs at stable doses throughout the study. Combined remission at week 24 was the primary endpoint, defined as the clinical closure of all treated fistulas (absence of draining), as assessed by gentle finger compression, and absence of collections > 2 cm on magnetic resonance imaging. Significantly better results were obtained for combined remission in the ASC group than in the control group (50% *vs* 34%, *P* = 0.024)[51].

The STOMP study, conducted by the Mayo Clinic, was the first study to report the use of autologous ASC in a bioabsorbable matrix for the treatment of patients with a single fistula and no associated proctitis who did not respond to anti-TNF therapy. At 3 mo, 9 of the 12 patients (75%) had complete clinical healing, while at 6 mo 10 patients (83.3%) did, with similar rates of remission found in magnetic resonance imaging[52].

Injecting stem cells may be a valid alternative for complex PFCD that cannot be treated by conventional surgical methods. More evidence is required from adequately powered randomized clinical trials.

***PISA trial***

The PISA trial was a multicenter, prospective, randomized, controlled study comparing 3 groups: One that received a long-term seton (1 year), one that received anti-TNFs for 1 year, and a third that underwent surgical closure of the PFCD with either an endorectal advancement flap or LIFT, after 2 mo of anti-TNF. Before randomization, all patients underwent seton placement under general anesthesia, received antibiotics (metronidazole) for 2 wk and 6-mercaptopurine. The results showed a higher rate of reintervention for the long-term group seton group (10/15 *vs* 6/15 anti-TNF *vs* 3/14 surgical closure). The results suggest that chronic treatment with a long-term seton cannot be recommended as the only treatment for PFCD[12].

***Endoscopic therapy for perianal disease***

Partial endoscopic fistulotomy can be performed on intersphincteric fistulas through incision and endoscopic drainage. Although incision and endoscopic drainage can also be performed with PFCD-associated perianal abscesses, it would be a temporary measure since more definitive therapy is needed, such as seton placement or fistulotomy. Abscesses associated with a perianal fistula can also be treated with endoscopy-guided seton placement[29,49].

***Intralesional anti-TNF***

In 7 case series, all with a small sample size (from 9 to 33 patients), infliximab (15 and 25 mg every 4 wk) or adalimumab (20 or 40 mg every 2 wk) was injected locally around the fistula, and closure was reported in 31%-75% of cases. The advantage is that injections can be easily repeated[10]. In a recent review evaluating 6 case series (including 2 studies with adalimumab injection), for a total of 92 patients enrolled, short-term efficacy (defined as complete or partial response) ranged from 40% to 100% without any significant adverse events[53]. Although local injection of infliximab appears to be safe and possibly effective, these studies involved few patients, had a short follow-up and no control group, in addition to a lack of standardization of the evaluated criteria and results.

***Hyperbaric oxygen therapy***

It has been proposed that hypoxia contributes to the onset and maintenance of inflammation, either as a causative or modifying factor, and its role as a trigger of inflammation has been demonstrated both *in vitro* and *in vivo*. Hyperbaric oxygen therapy (*i.e*., inhaling pure oxygen in chambers at pressure > 1 atm) provides an option to optimize fibroblast proliferation and leukocyte activity[49], as well as to reduce hypoxia duration by altering the secretion of interleukin 1 (IL-1), IL-6, IL-2, and TNF and promoting angiogenesis. This technique has been effectively used to treat perianal disease, pyoderma gangrenosum, steroid-refractory ulcerative colitis, and persistent perineal sinus following proctectomy in inflammatory bowel disease. Regarding response to hyperbaric oxygen therapy among patients with perineal or fistulizing CD, rates range from 50% to 70% for complete response, from 9% to 41% for partial response, and from 12% to 20% for no response; a response rate of 88% has been reported in a systematic review of 40 patients with perianal disease refractory to conventional therapy[49,54,55].

Mild adverse effects have been associated with hyperbaric oxygen therapy, and they appear to be related to alterations in oxygen toxicity and barometric pressure. Trauma to the middle ear or sinus is reported as the most common complication, whereas rare complications have been observed in patients with underlying pulmonary disease and include pneumothorax, air embolism, and transient vision loss. Cataract maturation has been reported in more than 150 treated patients[49,56].

Hyperbaric oxygen therapy may be suggested as a last-line option in the treatment of chronic perianal CD refractory to other therapies or as an adjuvant to surgery, but controlled trials are still needed before it can be recommended for the management of PFCD[10]. This treatment is very time consuming and the effect might not continue if treatment is stopped.

***Deviation***

Deviation is a therapeutic option for patients with refractory perianal CD. However, due to its temporary character, it is not always feasible. In a systematic review including 15 studies, for a total of 556 patients enrolled, a low rate (33%) of intestinal transit reconstruction was observed after deviation[57].

***Proctectomy***

Proctectomy is the final treatment option for severe perianal CD refractory to aggressive medical treatment and to surgery. Proctocolectomy is preferred to rectal preservation in patients with concurrent Crohn's colitis and perineal disease because of the high rate of persistent rectal stump disease in cases in which the stump is left in place[4]. A feared complication after these techniques is inadequate healing of the perineal wound or the emergence of a perineal sinus of persistent drainage[58]. Proctectomy must include the mesorectum, since proinflammatory cells in the Crohn’s mesorectum might fuel persistent inflammation in the pelvis. The cavity produced after a TME-type proctectomy can be filled with omentum[59].

A preoperative diagnosis of CD is generally considered a contraindication to ileal pouch-anal anastomosis (IPAA), although restorative proctocolectomy with the IPAA technique is a possibility in some Crohn’s colitis patients. No significant difference was found in pouch failure between CD and ulcerative colitis[60]. Li *et al*[61] suggested a very select group of patients in whom surgery may be an appropriate treatment: Those without perianal, small bowel, or mesenteric disease. Shen *et al*[62], on the other hand, reported that patients with a preoperative diagnosis of CD who undergo IPAA often develop CD in the pouch after surgery. Multicenter studies with a large number of patients will be necessary to better define indications for IPAA in CD.

**CONCLUSION**

Although medical treatment is the basic approach to perianal CD, surgical treatment is also essential. Before treating the fistula medically or surgically, a seton must be placed. However, there is still no consensus about the best approach. There is no doubt that, in the presence of serious or recurrent disease, aggressive surgical treatment should be considered. In addition, some patients will require a stoma or even a proctectomy. In cases of deviation, always consider closure after controlling for proctitis. It should also be noted that perianal CD should be managed by a multidisciplinary team.

**REFERENCES**

1 **Bolshinsky V**, Church J. Management of Complex Anorectal and Perianal Crohn's Disease. *Clin Colon Rectal Surg* 2019; **32**: 255-260 [PMID: 31275071 DOI: 10.1055/s-0039-1683907]

2 **Kotze PG**, Magro DO, Saab B, Saab MP, Pinheiro LV, Olandoski M, Ayrizono MLS, Martinez CAR, Coy CSR. Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease. *Intest Res* 2018; **16**: 62-68 [PMID: 29422799 DOI: 10.5217/ir.2018.16.1.62]

3 **Rackovsky O**, Hirten R, Ungaro R, Colombel JF. Clinical updates on perianal fistulas in Crohn's disease. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 597-605 [PMID: 29792734 DOI: 10.1080/17474124.2018.1480936]

4 **Truong A**, Zaghiyan K, Fleshner P. Anorectal Crohn's Disease. *Surg Clin North Am* 2019; **99**: 1151-1162 [PMID: 31676054 DOI: 10.1016/j.suc.2019.08.012]

5 **Bislenghi G**, Wolthuis A, Van Assche G, Vermeire S, Ferrante M, D'Hoore A. Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease. *Expert Opin Biol Ther* 2019; **19**: 607-616 [PMID: 31121104 DOI: 10.1080/14712598.2019.1623876]

6 **Sandborn WJ**, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. *Gastroenterology* 2003; **125**: 1508-1530 [PMID: 14598268 DOI: 10.1016/j.gastro.2003.08.025]

7 **Van Assche G**, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D'Hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. *Am J Gastroenterol* 2003; **98**: 332-339 [PMID: 12591051 DOI: 10.1016/S0002-9270(02)05909-9]

8 **Seyfried S**, Herold A. Management of Perianal Fistulas in Crohn's Disease. *Visc Med* 2019; **35**: 338-343 [PMID: 31934580 DOI: 10.1159/000504103]

9 **Molendijk I**, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ. Disappointing durable remission rates in complex Crohn's disease fistula. *Inflamm Bowel Dis* 2014; **20**: 2022-2028 [PMID: 25159455 DOI: 10.1097/MIB.0000000000000148]

10 **Boscá MM**, Alós R, Maroto N, Gisbert JP, Beltrán B, Chaparro M, Nos P, Mínguez M, Hinojosa J. Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. *Gastroenterol Hepatol* 2020; **43**: 155-168 [PMID: 31870681 DOI: 10.1016/j.gastrohep.2019.09.012]

11 **Kotze PG**, Albuquerque IC, da Luz Moreira A, Tonini WB, Olandoski M, Coy CS. Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn's disease: a Brazilian multicenter observational study. *Arq Gastroenterol* 2014; **51**: 284-289 [PMID: 25591155 DOI: 10.1590/S0004-28032014000400004]

12 **Wasmann KA**, de Groof EJ, Stellingwerf ME, D'Haens GR, Ponsioen CY, Gecse KB, Dijkgraaf MGW, Gerhards MF, Jansen JM, Pronk A, van Tuyl SAC, Zimmerman DDE, Bruin KF, Spinelli A, Danese S, van der Bilt JDW, Mundt MW, Bemelman WA, Buskens CJ. Treatment of Perianal Fistulas in Crohn's Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial. *J Crohns Colitis* 2020; **14**: 1049-1056 [PMID: 31919501 DOI: 10.1093/ecco-jcc/jjaa004]

13 **Gecse KB**, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, Panés J, van Assche G, Liu Z, Hart A, Levesque BG, D'Haens G; World Gastroenterology Organization, International Organisation for Inflammatory Bowel Diseases IOIBD, European Society of Coloproctology and Robarts Clinical Trials; World Gastroenterology Organization International Organisation for Inflammatory Bowel Diseases IOIBD European Society of Coloproctology and Robarts Clinical Trials. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. *Gut* 2014; **63**: 1381-1392 [PMID: 24951257 DOI: 10.1136/gutjnl-2013-306709]

14 **Sulz MC**, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F; on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Treatment Algorithms for Crohn's Disease. *Digestion* 2020; 101 Suppl 1: 43-57 [PMID: 32172251 DOI: 10.1159/000506364]

15 **Williams JG**, MacLeod CA, Rothenberger DA, Goldberg SM. Seton treatment of high anal fistulae. *Br J Surg* 1991; **78**: 1159-1161 [PMID: 1958973 DOI: 10.1002/bjs.1800781004]

16 **Thornton M**, Solomon MJ. Long-term indwelling seton for complex anal fistulas in Crohn's disease. *Dis Colon Rectum* 2005; **48**: 459-463 [PMID: 15719188 DOI: 10.1007/s10350-004-0830-6]

17 **Takesue Y**, Ohge H, Yokoyama T, Murakami Y, Imamura Y, Sueda T. Long-term results of seton drainage on complex anal fistulae in patients with Crohn's disease. *J Gastroenterol* 2002; **37**: 912-915 [PMID: 12483246 DOI: 10.1007/s005350200153]

18 **Galis-Rozen E**, Tulchinsky H, Rosen A, Eldar S, Rabau M, Stepanski A, Klausner JM, Ziv Y. Long-term outcome of loose seton for complex anal fistula: a two-centre study of patients with and without Crohn's disease. *Colorectal Dis* 2010; **12**: 358-362 [PMID: 19220385 DOI: 10.1111/j.1463-1318.2009.01796.x]

19 **Panés J**, Rimola J. Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 652-664 [PMID: 28790453 DOI: 10.1038/nrgastro.2017.104]

20 **van Koperen PJ**, Safiruddin F, Bemelman WA, Slors JF. Outcome of surgical treatment for fistula in ano in Crohn's disease. *Br J Surg* 2009; **96**: 675-679 [PMID: 19434701 DOI: 10.1002/bjs.6608]

21 **Soltani A**, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn's fistula-in-ano. *Dis Colon Rectum* 2010; **53**: 486-495 [PMID: 20305451 DOI: 10.1007/DCR.0b013e3181ce8b01]

22 **Jarrar A**, Church J. Advancement flap repair: a good option for complex anorectal fistulas. *Dis Colon Rectum* 2011; **54**: 1537-1541 [PMID: 22067182 DOI: 10.1097/DCR.0b013e31822d7ddd]

23 **Roper MT**, Trinidad SM, Ramamoorthy SL, Parry LA, Lopez NE, Khaitov S, Steinhagen R, Eisenstein SG. Endorectal Advancement Flaps for Perianal Fistulae in Crohn's Disease: Careful Patient Selection Leads to Optimal Outcomes. *J Gastrointest Surg* 2019; **23**: 2277-2284 [PMID: 30980232 DOI: 10.1007/s11605-019-04205-0]

24 **Stellingwerf ME**, van Praag EM, Tozer PJ, Bemelman WA, Buskens CJ. Systematic review and meta-analysis of endorectal advancement flap and ligation of the intersphincteric fistula tract for cryptoglandular and Crohn's high perianal fistulas. *BJS Open* 2019; **3**: 231-241 [PMID: 31183438 DOI: 10.1002/bjs5.50129]

25 **van Praag EM**, Stellingwerf ME, van der Bilt JDW, Bemelman WA, Gecse KB, Buskens CJ. Ligation of the Intersphincteric Fistula Tract and Endorectal Advancement Flap for High Perianal Fistulas in Crohn's Disease: A Retrospective Cohort Study. *J Crohns Colitis* 2020; **14**: 757-763 [PMID: 31696918 DOI: 10.1093/ecco-jcc/jjz181]

26 **Rojanasakul A**. LIFT procedure: a simplified technique for fistula-in-ano. *Tech Coloproctol* 2009; **13**: 237-240 [PMID: 19636496 DOI: 10.1007/s10151-009-0522-2]

27 **Gingold DS**, Murrell ZA, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn's disease. *Ann Surg* 2014; **260**: 1057-1061 [PMID: 24374520 DOI: 10.1097/SLA.0000000000000479]

28 **Kamiński JP**, Zaghiyan K, Fleshner P. Increasing experience of ligation of the intersphincteric fistula tract for patients with Crohn's disease: what have we learned? *Colorectal Dis* 2017; **19**: 750-755 [PMID: 28371062 DOI: 10.1111/codi.13668]

29 **Kotze PG**, Shen B, Lightner A, Yamamoto T, Spinelli A, Ghosh S, Panaccione R. Modern management of perianal fistulas in Crohn's disease: future directions. *Gut* 2018; **67**: 1181-1194 [PMID: 29331943 DOI: 10.1136/gutjnl-2017-314918]

30 **Senéjoux A**, Siproudhis L, Abramowitz L, Munoz-Bongrand N, Desseaux K, Bouguen G, Bourreille A, Dewit O, Stefanescu C, Vernier G, Louis E, Grimaud JC, Godart B, Savoye G, Hebuterne X, Bauer P, Nachury M, Laharie D, Chevret S, Bouhnik Y; Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif [GETAID]. Fistula Plug in Fistulising Ano-Perineal Crohn's Disease: a Randomised Controlled Trial. *J Crohns Colitis* 2016; **10**: 141-148 [PMID: 26351393 DOI: 10.1093/ecco-jcc/jjv162]

31 **Grimaud JC**, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Sénéjoux A, Vitton V, Gambiez L, Flourié B, Hébuterne X, Louis E, Coffin B, De Parades V, Savoye G, Soulé JC, Bouhnik Y, Colombel JF, Contou JF, François Y, Mary JY, Lémann M; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. *Gastroenterology* 2010; **138**: 2275-2281, 2281.e1 [PMID: 20178792 DOI: 10.1053/j.gastro.2010.02.013]

32 **Champagne BJ**, O'Connor LM, Ferguson M, Orangio GR, Schertzer ME, Armstrong DN. Efficacy of anal fistula plug in closure of cryptoglandular fistulas: long-term follow-up. *Dis Colon Rectum* 2006; **49**: 1817-1821 [PMID: 17082891 DOI: 10.1007/s10350-006-0755-3]

33 **Schwandner T**, Roblick MH, Kierer W, Brom A, Padberg W, Hirschburger M. Surgical treatment of complex anal fistulas with the anal fistula plug: a prospective, multicenter study. *Dis Colon Rectum* 2009; **52**: 1578-1583 [PMID: 19690485 DOI: 10.1007/DCR.0b013e3181a8fbb7]

34 **Ellis CN**. Outcomes with the use of bioprosthetic grafts to reinforce the ligation of the intersphincteric fistula tract (BioLIFT procedure) for the management of complex anal fistulas. *Dis Colon Rectum* 2010; **53**: 1361-1364 [PMID: 20847616 DOI: 10.1007/DCR.0b013e3181ec4470]

35 **Cintron JR**, Abcarian H, Chaudhry V, Singer M, Hunt S, Birnbaum E, Mutch MG, Fleshman J. Treatment of fistula-in-ano using a porcine small intestinal submucosa anal fistula plug. *Tech Coloproctol* 2013; **17**: 187-191 [PMID: 23053440 DOI: 10.1007/s10151-012-0897-3]

36 **Herold A**, Ommer A, Fürst A, Pakravan F, Hahnloser D, Strittmatter B, Schiedeck T, Hetzer F, Aigner F, Berg E, Roblick M, Bussen D, Joos A, Vershenya S. Results of the Gore Bio-A fistula plug implantation in the treatment of anal fistula: a multicentre study. *Tech Coloproctol* 2016; **20**: 585-590 [PMID: 27418257 DOI: 10.1007/s10151-016-1505-8]

37 **Schwandner O**. Video-assisted anal fistula treatment (VAAFT) combined with advancement flap repair in Crohn's disease. *Tech Coloproctol* 2013; **17**: 221-225 [PMID: 23179892 DOI: 10.1007/s10151-012-0921-7]

38 **Garg P**, Singh P. Video-Assisted Anal Fistula Treatment (VAAFT) in Cryptoglandular fistula-in-ano: A systematic review and proportional meta-analysis. *Int J Surg* 2017; **46**: 85-91 [PMID: 28882770 DOI: 10.1016/j.ijsu.2017.08.582]

39 **Adegbola SO**, Sahnan K, Tozer PJ, Strouhal R, Hart AL, Lung PFC, Phillips RKS, Faiz O, Warusavitarne J. Symptom Amelioration in Crohn's Perianal Fistulas Using Video-Assisted Anal Fistula Treatment (VAAFT). *J Crohns Colitis* 2018; **12**: 1067-1072 [PMID: 29800373 DOI: 10.1093/ecco-jcc/jjy071]

40 **Emile SH**, Elfeki H, Shalaby M, Sakr A. A Systematic review and meta-analysis of the efficacy and safety of video-assisted anal fistula treatment (VAAFT). *Surg Endosc* 2018; **32**: 2084-2093 [PMID: 29052068 DOI: 10.1007/s00464-017-5905-2]

41 **Moy J**, Bodzin J. Carbon dioxide laser ablation of perianal fistulas in patients with Crohn's disease: experience with 27 patients. *Am J Surg* 2006; **191**: 424-427 [PMID: 16490560 DOI: 10.1016/j.amjsurg.2005.10.050]

42 **Wilhelm A**. A new technique for sphincter-preserving anal fistula repair using a novel radial emitting laser probe. *Tech Coloproctol* 2011; **15**: 445-449 [PMID: 21845480 DOI: 10.1007/s10151-011-0726-0]

43 **Wilhelm A**, Fiebig A, Krawczak M. Five years of experience with the FiLaC™ laser for fistula-in-ano management: long-term follow-up from a single institution. *Tech Coloproctol* 2017; **21**: 269-276 [PMID: 28271331 DOI: 10.1007/s10151-017-1599-7]

44 **Elfeki H**, Shalaby M, Emile SH, Sakr A, Mikael M, Lundby L. A systematic review and meta-analysis of the safety and efficacy of fistula laser closure. *Tech Coloproctol* 2020; **24**: 265-274 [PMID: 32065306 DOI: 10.1007/s10151-020-02165-1]

45 **Stijns J**, van Loon YT, Clermonts SHEM, Gӧttgens KW, Wasowicz DK, Zimmerman DDE. Implementation of laser ablation of fistula tract (LAFT) for perianal fistulas: do the results warrant continued application of this technique? *Tech Coloproctol* 2019; **23**: 1127-1132 [PMID: 31781883 DOI: 10.1007/s10151-019-02112-9]

46 **Alam A**, Lin F, Fathallah N, Pommaret E, Aubert M, Lemarchand N, Abbes L, Spindler L, Portal A, de Parades V. FiLaC® and Crohn's disease perianal fistulas: a pilot study of 20 consecutive patients. *Tech Coloproctol* 2020; **24**: 75-78 [PMID: 31893324 DOI: 10.1007/s10151-019-02134-3]

47 **Seyfried S**, Bussen D, Joos A, Galata C, Weiss C, Herold A. Fistulectomy with primary sphincter reconstruction. *Int J Colorectal Dis* 2018; **33**: 911-918 [PMID: 29651553 DOI: 10.1007/s00384-018-3042-6]

48 **Herold A**, Joos A, Hellmann U, Bussen D. Treatment of high anal fistula: Is fistulectomy with primary sphincter repair an option? [Abstract no. OP48]. Abstracts of the Fourth Annual Meeting of the European Society of Coloproctology. September 23-26, 2009. Prague, Czech Republic. *Colorectal Dis* 2009; **11** Suppl 2: 1-57 [PMID: 19674030 DOI: 10.1111/j.1463-1318.2009.01974.x]

49 **Wang X**, Shen B. Advances in Perianal Disease Associated with Crohn's Disease-Evolving Approaches. *Gastrointest Endosc Clin N Am* 2019; **29**: 515-530 [PMID: 31078250 DOI: 10.1016/j.giec.2019.02.011]

50 **Kotze PG**, Spinelli A, Lightner AL. Cell-based Therapy for Perianal Fistulising Crohn's Disease. *Curr Pharm Des* 2019; **25**: 41-46 [PMID: 31092172 DOI: 10.2174/1381612825666190308095651]

51 **Panés J**, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet* 2016; **388**: 1281-1290 [PMID: 27477896 DOI: 10.1016/S0140-6736(16)31203-X]

52 **Lightner AL**, Wang Z, Zubair AC, Dozois EJ. A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn's Disease: Progress Made and Future Directions. *Dis Colon Rectum* 2018; **61**: 629-640 [PMID: 29578916 DOI: 10.1097/DCR.0000000000001093]

53 **Adegbola SO**, Sahnan K, Tozer PJ, Phillips RK, Faiz OD, Warusavitarne J, Hart A. Review of local injection of anti-TNF for perianal fistulising Crohn's disease. *Int J Colorectal Dis* 2017; **32**: 1539-1544 [PMID: 28900730 DOI: 10.1007/s00384-017-2899-0]

54 **Dulai PS**, Buckey JC Jr, Raffals LE, Swoger JM, Claus PL, OʼToole K, Ptak JA, Gleeson MW, Widjaja CE, Chang JT, Adler JM, Patel N, Skinner LA, Haren SP, Goldby-Reffner K, Thompson KD, Siegel CA. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. *Am J Gastroenterol* 2018; **113**: 1516-1523 [PMID: 29453383 DOI: 10.1038/s41395-018-0005-z]

55 **Bekheit M**, Baddour N, Katri K, Taher Y, El Tobgy K, Mousa E. Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series. *BMJ Open Gastroenterol* 2016; **3**: e000082 [PMID: 27195128 DOI: 10.1136/bmjgast-2016-000082]

56 **Dulai PS**, Gleeson MW, Taylor D, Holubar SD, Buckey JC, Siegel CA. Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. *Aliment Pharmacol Ther* 2014; **39**: 1266-1275 [PMID: 24738651 DOI: 10.1111/apt.12753]

57 **Singh S**, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, Hart AL, Sandborn WJ, Loftus EV Jr. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. *Aliment Pharmacol Ther* 2015; **42**: 783-792 [PMID: 26264359 DOI: 10.1111/apt.13356]

58 **Yamamoto T**, Bain IM, Allan RN, Keighley MR. Persistent perineal sinus after proctocolectomy for Crohn's disease. *Dis Colon Rectum* 1999; **42**: 96-101 [PMID: 10211527 DOI: 10.1007/BF02235190]

59 **de Groof EJ**, van der Meer JHM, Tanis PJ, de Bruyn JR, van Ruler O, D'Haens GRAM, van den Brink GR, Bemelman WA, Wildenberg ME, Buskens CJ. Persistent Mesorectal Inflammatory Activity is Associated With Complications After Proctectomy in Crohn's Disease. *J Crohns Colitis* 2019; **13**: 285-293 [PMID: 30203027 DOI: 10.1093/ecco-jcc/jjy131]

60 **Le Q**, Melmed G, Dubinsky M, McGovern D, Vasiliauskas EA, Murrell Z, Ippoliti A, Shih D, Kaur M, Targan S, Fleshner P. Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn's disease. *Inflamm Bowel Dis* 2013; **19**: 30-36 [PMID: 22467562 DOI: 10.1002/ibd.22955]

61 **Li Y**, Wu B, Shen B. Diagnosis and differential diagnosis of Crohn's disease of the ileal pouch. *Curr Gastroenterol Rep* 2012; **14**: 406-413 [PMID: 22855236 DOI: 10.1007/s11894-012-0282-4]

62 **Shen B**, Patel S, Lian L. Natural history of Crohn's disease in patients who underwent intentional restorative proctocolectomy with ileal pouch-anal anastomosis. *Aliment Pharmacol Ther* 2010; **31**: 745-753 [PMID: 20047579 DOI: 10.1111/j.1365-2036.2009.04227.x]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** August 13, 2020

**First decision:** August 22, 2020

**Article in press:** September 29, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** M'Koma A **S-Editor:** Gong ZM **L-Editor:** A **P-Editor:** Li JH

**Table 1 The results of long-term seton procedures**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Year** | ***n*** | **Follow-up, mo (range)** | **Recurrence (%)** |
| William *et al*[15] | 1991 | 55 | 54 (6-120) | 0 |
| Thornton *et al*[16] | 2005 | 28 | 13 (2-81) | 21 |
| Takesue *et al*[17] | 2002 | 32 | 62 (25-133) | 3 (33) |
| Galis-Rozen *et al*[18] | 2010 | 17 | 8 (6-9) | 40 |

**Table 2 The results of flap procedures**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.**  | **Year** | ***n*** | **Healing (%)** | **Recurrence (R) or incontinence (I) (%)** |
| Van Koperen *et al*[20] | 2009 | 9 | 45 | 55 (R) |
| Soltani *et al*[21] | 2010 | 91 | 64 | 9.4 (I) |
| Church *et al*[22] | 2011 | 19 | 87 | NR |
| Roper *et al*[23] | 2019 | 39 | 92,6 | 19.5 (R) |
| Stellingwerf *et al*[24] | 2019 | 64 | 61 | 7.8 (I) |
| Praag *et al*[25] | 2019 | 21 | 60 | 19 (R) 15.8 (I) |

NR: not reported.

**Table 3 The results of ligation of the intersphincteric fistula tract procedures**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Year** | ***n*** | **Healing (%)** | **Recurrence (R) or incontinence (I) (%)** |
| Gingold *et al*[27] | 2014 | 15 | 60 | 40 (R) |
| Kaminski *et al*[28] | 2017 | 23 | 48 | 52 (R) |
| Praag *et al*[25] | 2019 | 19 | 89.5 | 21.1 (R), 21.4 (I) |
| Stellingwerf *et al*[24] | 2019 | 64 | 53 | 1.6 (I) |

**Table 4 The results of fibrin glue and plug procedures**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Year** | ***n*** | **Healing (%)** | **Recurrence (%)** |
| Champagne *et al*[32] | 2006 | 20 | 80 | 20 |
| Schwandner *et al*[33] | 2009 | 9 | 77 | 23 |
| Ellis *et al*[34] | 2010 | 12 | 66 | 34 |
| Cintron *et al*[35] | 2013 | 8 | 50 | 50 |
| Herold *et al*[36] | 2016 | 4 | 25 | 75 |

**Table 5 The results of video-assisted anal fistula treatment procedures**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Year** | ***n*** | **Healing (%)** | **Recurrence (R) Incontinence (I) (%)** |
| Schwandner *et al*[37] | 2013 | 13 | 82 | 0 (I) |
| Garg *et al*[38] | 2017 | 786 | 76 | 0 (I) |
| Adegbola *et al*[39] | 2018 | 25 | 84 | NR |
| Emili *et al*[40] | 2018 | 788 | 54,3 | 17.7 (R) |

NR: not reported.

**Table 6 The results of fistula-tract laser closure procedures**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Year** | ***n*** | **Healing (%)** | **Recurrence (%)** |
| Moy *et al*[41] | 2006 | 27 | NR | NR |
| Wilhelm *et al*[43] | 2017 | 13 | 69.2 | 0 (I) |
| Stijins *et al*[45] | 2019 | 20 | 20 | NR |
| Alam *et al*[46] | 2020 | 20 | 54 | NR |

NR: not reported.

**Table 7 The results of fistulectomy with primary sphincter reconstruction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Year** | ***n*** | **Healing (%)** | **Recurrence (%)** |
| Herold *et al*[48] | 2009 | 10 | 86 | 14 |
| Seyfried *et al*[47] | 2018 | 24 | > 85 | ? |